AR085806A1 - Inhibidores triciclicos de girasa - Google Patents
Inhibidores triciclicos de girasaInfo
- Publication number
- AR085806A1 AR085806A1 ARP120100830A ARP120100830A AR085806A1 AR 085806 A1 AR085806 A1 AR 085806A1 AR P120100830 A ARP120100830 A AR P120100830A AR P120100830 A ARP120100830 A AR P120100830A AR 085806 A1 AR085806 A1 AR 085806A1
- Authority
- AR
- Argentina
- Prior art keywords
- substituent
- optionally substituted
- carbon
- length
- interacting
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Procesos de obtención, composiciones farmacéuticas y compuestos intermediarios.Reivindicación 1: Un compuesto que tiene la estructura de fórmula (1) o sales farmacéuticamente aceptables, ésteres, y prodrogas del mismo, donde L es O ó S; R8 es H o un sustituyente interactuante con una longitud de aproximadamente 1 - 5 Å desde el punto de unión de carbono en el Anillo A hasta el átomo terminal en R8 y un ancho de aproximadamente 3,3 Å o menor; X, Y y Z se seleccionan en forma independiente entre el grupo que consiste en N, CRX, CRY, y CRZ, con la condición de que no más que dos de X, Y y Z son N, donde RX es H o un sustituyente interactuante con una longitud de aproximadamente 1 - 2 Å desde el carbono en CRX hasta el átomo terminal en RX; donde RY es H o un sustituyente interactuante con una longitud de aproximadamente 1 - 3 Å desde el carbono en CRY hasta el átomo terminal en RY; donde RZ es H o un sustituyente interactuante con una longitud de aproximadamente 1 - 2 Å desde el carbono en CRZ hasta el átomo terminal en RZ; R2 es un anillo arilo o heteroarilo de 6 miembros que contiene 0 - 3 heteroátomos O, S, o N, opcionalmente sustituido con 0 - 3 sustituyentes no interferentes, donde 2 sustituyentes no interferentes adyacentes sobre R2 pueden formar uno o más anillos fusionados con el anillo arilo o heteroarilo de 6 miembros; donde el anillo arilo o heteroarilo de 6 miembros de R2 tiene un CH en la posición inmediatamente adyacente a la posición donde R2 se une a L; R4 es: H; un ORa opcionalmente sustituido; una amina secundaria o terciaria opcionalmente sustituida unida al anillo C a través del N de la amina secundaria o terciaria; o un residuo cíclico o heterocíclico insaturado de 5 - 10 miembros opcionalmente sustituido que contiene 0 - 3 heteroátomos N, O ó S; donde el sustituyente opcional es 0 - 3 sustituyentes no interferentes; donde Ra es un arilo o heteroarilo de 5 - 6 miembros que contiene 0 - 3 heteroátomos O, S, o N opcionalmente sustituido con 0 - 3 sustituyentes no interferentes; donde el sustituyente R4 no se proyecta más que 3 Å por debajo del plano de los anillos A, B y C hacia el piso del bolsillo de unión de GyrB/ParE en el estado unido; y donde R4 no interfiere estéricamente con R2 o Z cuando el compuesto se encuentra en el estado unido.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161453011P | 2011-03-15 | 2011-03-15 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR085806A1 true AR085806A1 (es) | 2013-10-30 |
Family
ID=45879060
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP120100830A AR085806A1 (es) | 2011-03-15 | 2012-03-14 | Inhibidores triciclicos de girasa |
Country Status (15)
Country | Link |
---|---|
US (2) | US9732083B2 (es) |
EP (1) | EP2686320B1 (es) |
JP (1) | JP6140083B2 (es) |
KR (2) | KR20140059164A (es) |
CN (1) | CN103562208B (es) |
AR (1) | AR085806A1 (es) |
AU (1) | AU2012229997B2 (es) |
BR (1) | BR112013023266B8 (es) |
CA (1) | CA2829939C (es) |
IL (1) | IL228220A (es) |
MX (1) | MX345780B (es) |
RU (1) | RU2626979C2 (es) |
TW (1) | TWI527818B (es) |
WO (1) | WO2012125746A1 (es) |
ZA (1) | ZA201307583B (es) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2626979C2 (ru) | 2011-03-15 | 2017-08-02 | Мерк Шарп Энд Дохме Корп. | Трициклические ингибиторы гиразы |
PT2807165T (pt) * | 2012-01-27 | 2019-07-12 | Univ Montreal | Derivados de pirimido[4,5-b]indole e sua utilização na expansão de células estaminais hematopoiéticas |
EP2895488A1 (en) * | 2012-09-12 | 2015-07-22 | Trius Therapeutics, Inc. | Tricyclic gyrase inhibitors for use as antibacterial agents |
CN103304488B (zh) * | 2013-06-13 | 2015-12-09 | 暨明医药科技(苏州)有限公司 | 光学纯2-(1-羟基乙基)-5-羟基嘧啶的制备方法 |
US10385055B2 (en) | 2013-09-11 | 2019-08-20 | Merck Sharp & Dohme Corp. | Tricyclic gyrase inhibitors |
EP3102203A2 (en) | 2014-02-03 | 2016-12-14 | Spero Gyrase, Inc. | Antibacterial combinations comprising polymyxin |
WO2015150337A1 (en) * | 2014-04-01 | 2015-10-08 | Amakem Nv | Lim kinase inhibitors |
RU2019133662A (ru) | 2017-03-24 | 2021-04-26 | Тайсо Фармасьютикал Ко., Лтд. | Производное 2(1h)-хинолинона |
EP3601282B1 (en) * | 2017-03-30 | 2021-07-21 | F. Hoffmann-La Roche AG | Novel pyrido[2,3-b]indole compounds for the treatment and prophylaxis of bacterial infection |
CN108504647B (zh) * | 2018-03-09 | 2021-11-05 | 中山大学 | 一种dna促旋酶的药物结合口袋及其应用 |
CN112204037A (zh) | 2018-05-28 | 2021-01-08 | 豪夫迈·罗氏有限公司 | 用于治疗和预防细菌感染的新氧代喹嗪化合物 |
CN112752762A (zh) * | 2018-09-26 | 2021-05-04 | 豪夫迈·罗氏有限公司 | 用于治疗和预防细菌感染的取代的吡啶并吲哚 |
JP7465266B2 (ja) * | 2018-11-27 | 2024-04-10 | エフ. ホフマン-ラ ロシュ アーゲー | 細菌感染症の治療と予防のための三環式化合物 |
CN113166144A (zh) | 2018-11-27 | 2021-07-23 | 豪夫迈·罗氏有限公司 | 用于治疗和预防细菌感染的芳基化合物 |
EP3898639A1 (en) | 2018-12-20 | 2021-10-27 | F. Hoffmann-La Roche AG | Oxopyrido[1,2-a]pyrimidine compounds for the treatment and prophylaxis of bacterial infection |
CN114763357B (zh) * | 2021-01-15 | 2024-06-18 | 中国科学院上海药物研究所 | 吲哚并嘧啶三环类化合物及其制备方法和用途 |
Family Cites Families (48)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IN157280B (es) | 1983-07-15 | 1986-02-22 | Hoechst India | |
CA1336090C (en) | 1988-08-31 | 1995-06-27 | Isao Hayakawa | Spiro-substituted cyclic amines of quinolone derivatives |
DE4030059A1 (de) | 1990-09-22 | 1992-03-26 | Bayer Ag | Verfahren zur herstellung von 5-hydroxy-3,4,5,6-tetrahydro-pyrimidin-derivaten |
DE4032560A1 (de) | 1990-10-13 | 1992-04-16 | Bayer Ag | 7-(2,7-diazabicyclo(3.3.0)octyl)-3-chinolon- und -naphtyridoncarbonsaeure-derivate |
CA2130937A1 (en) | 1992-04-03 | 1993-10-14 | Gordon L. Bundy | Pharmaceutically active bicyclic-heterocyclic amines |
US5279359A (en) | 1992-06-26 | 1994-01-18 | Erickson Donald C | Rotary trisorption heat pump |
US5350791A (en) | 1992-07-02 | 1994-09-27 | Henkel Corporation | Hydrophilicizing treatment for metal objects |
US5527910A (en) | 1992-12-30 | 1996-06-18 | Cheil Foods & Chemicals, Inc. | Pyridone carboxylic acid compounds and their uses for treating infectious diseases caused by bacteria |
RU2158127C2 (ru) * | 1994-12-23 | 2000-10-27 | Варнер-Ламберт Компани | Способы ингибирования тирозинкиназы рецептора эпидермального фактора роста, азотсодержащие трициклические соединения, фармацевтическая композиция, предназначенная для введения ингибитора тирозинкиназы рецептора эпидермального фактора роста, например, erb-b2, erb-b3 или erb-b4, и противозачаточная композиция |
CN1177354A (zh) | 1995-03-02 | 1998-03-25 | 法玛西雅厄普约翰美国公司 | 嘧啶并[4,5-b]吲哚 |
HUP9900330A3 (en) * | 1995-07-06 | 2001-08-28 | Novartis Ag | Pyrrolopyrimidines and processes for the preparation thereof |
AU7890598A (en) | 1996-12-27 | 1998-07-31 | Yoshitomi Pharmaceutical Industries, Ltd. | Fused pyrimidine compounds and medicinal use thereof |
DK0964865T3 (da) | 1997-01-08 | 2003-05-05 | Upjohn Co | Farmaceutisk virksomme tricycliske aminer |
SK284511B6 (sk) | 1997-07-29 | 2005-05-05 | Pharmacia & Upjohn Company | Samoemulgujúce formulácie pre lipofilné zlúčeniny |
JP2002510688A (ja) | 1998-04-02 | 2002-04-09 | ニューロゲン コーポレイション | アミノアルキル置換9H−ピリジノ[2,3−b]インドールおよび9H−ピリミジノ[4,5−b]インドール誘導体 |
WO1999051598A1 (en) | 1998-04-02 | 1999-10-14 | Neurogen Corporation | SUBSTITUTED 9H-PYRIDINO[2,3-b]INDOLE AND 9H-PYRIMIDINO[4,5-b]INDOLE DERIVATIVES: SELECTIVE NEUROPEPTIDE y RECEPTOR LIGANDS |
US6147085A (en) | 1999-04-01 | 2000-11-14 | Neurogen Corporation | Aminoalkyl substituted 9H-pyridino[2,3-b] indole and 9H-pyrimidino[4,5-b] indole derivatives |
JP2000038350A (ja) | 1998-05-18 | 2000-02-08 | Yoshitomi Pharmaceut Ind Ltd | 糖尿病治療薬 |
JP2002543200A (ja) | 1999-04-30 | 2002-12-17 | ニューロゲン コーポレイション | 9H−ピリミド[4、5−b]インドール誘導体:CRF1特異性リガンド |
EA005585B1 (ru) | 2000-01-24 | 2005-04-28 | Уорнер-Ламберт Компани | 3-аминохиназолин-2,4-дионовые антибактериальные агенты |
FR2816509B1 (fr) | 2000-11-15 | 2004-02-06 | Sod Conseils Rech Applic | Association d'inhibiteurs de calpaine et de piegeurs des formes reactives de l'oxygene |
CA2464934A1 (en) | 2001-10-31 | 2003-05-08 | Bayer Healthcare Ag | Pyrimido [4,5-b] indole derivatives |
WO2003062443A2 (en) | 2001-11-08 | 2003-07-31 | Antex Pharma, Inc. | Novel substituted alkane compounds and uses thereof |
WO2003057149A2 (en) | 2001-12-28 | 2003-07-17 | Bayer Corporation | 4-substituted fused heteropyrimidines and fused hetero-4-pyrimidones |
AR042667A1 (es) | 2002-12-26 | 2005-06-29 | Taisho Pharmaceutical Co Ltd | Derivados de pirrolopirimidina y pirrolopiridina sustituidos con un grupo amino ciclico |
AU2003300522A1 (en) * | 2002-12-27 | 2004-07-22 | Bayer Healthcare Ag | 4-phenyl-pyrimido (4,5-b) indole derivatives |
ES2344007T3 (es) | 2003-10-14 | 2010-08-16 | The Arizona Board Of Regents On Behalf Of The University Of Arizona | Inhibidores proteina quinasa. |
US20090099165A1 (en) | 2003-10-14 | 2009-04-16 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Protein Kinase Inhibitors |
US20080051414A1 (en) | 2003-10-14 | 2008-02-28 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Protein Kinase Inhibitors |
US20090143399A1 (en) | 2003-10-14 | 2009-06-04 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Protein Kinase Inhibitors |
JP2007161585A (ja) | 2004-06-25 | 2007-06-28 | Taisho Pharmaceut Co Ltd | 環状アミノ基で置換されているピロロピリミジン及びピロロピリジン誘導体 |
JP2006036762A (ja) | 2004-06-25 | 2006-02-09 | Taisho Pharmaceut Co Ltd | 環状アミノ基で置換されているピロロピリミジン及びピロロピリジン誘導体 |
WO2008007113A2 (en) | 2006-07-14 | 2008-01-17 | Astex Therapeutics Limited | Pharmaceutical combinations |
JP2008539277A (ja) | 2005-04-28 | 2008-11-13 | スーパージェン, インコーポレイテッド | プロテインキナーゼインヒビター |
DE602005010421D1 (de) * | 2005-08-05 | 2008-11-27 | Hybrigenics Sa | Neue Cysteine Protease Hemmers und ihre therapeutische Anwendungen |
WO2007025090A2 (en) | 2005-08-25 | 2007-03-01 | Kalypsys, Inc. | Heterobicyclic and - tricyclic inhibitors of mapk/erk kinase |
JP2007169216A (ja) | 2005-12-22 | 2007-07-05 | Taisho Pharmaceut Co Ltd | 環状アミノ基で置換されているピロロピリミジン及びピロロピリジン誘導体 |
US20080207632A1 (en) | 2006-10-31 | 2008-08-28 | Supergen, Inc. | Protein kinase inhibitors |
EP2170886A1 (en) | 2007-07-02 | 2010-04-07 | Cancer Research Technology Limited | 9h-pyrimido[4,5-b]indoles, 9h-pyrido[4',3':4,5]pyrrolo[2,3-d]pyridines, and 9h-1,3,6,9-tetraaza-fluorenes as chk1 kinase function inhibitors |
US7982035B2 (en) * | 2007-08-27 | 2011-07-19 | Duquesne University Of The Holy Spirit | Tricyclic compounds having antimitotic and/or antitumor activity and methods of use thereof |
US7960400B2 (en) * | 2007-08-27 | 2011-06-14 | Duquesne University Of The Holy Ghost | Tricyclic compounds having cytostatic and/or cytotoxic activity and methods of use thereof |
EP2229217A1 (en) | 2008-01-14 | 2010-09-22 | Irm Llc | Compositions and methods for treating cancers |
EP2326644B1 (en) * | 2008-08-02 | 2012-02-22 | Janssen Pharmaceutica N.V. | Urotensin ii receptor antagonists |
WO2011056739A1 (en) | 2009-11-03 | 2011-05-12 | Glaxosmithkline Llc | Compounds and methods |
RU2626979C2 (ru) * | 2011-03-15 | 2017-08-02 | Мерк Шарп Энд Дохме Корп. | Трициклические ингибиторы гиразы |
EP2895488A1 (en) * | 2012-09-12 | 2015-07-22 | Trius Therapeutics, Inc. | Tricyclic gyrase inhibitors for use as antibacterial agents |
US10385055B2 (en) * | 2013-09-11 | 2019-08-20 | Merck Sharp & Dohme Corp. | Tricyclic gyrase inhibitors |
WO2016067009A1 (en) * | 2014-10-28 | 2016-05-06 | Redx Pharma Plc | Compounds with activity against bacteria and mycobacteria |
-
2012
- 2012-03-14 RU RU2013140798A patent/RU2626979C2/ru active
- 2012-03-14 EP EP12710633.4A patent/EP2686320B1/en active Active
- 2012-03-14 BR BR112013023266A patent/BR112013023266B8/pt active IP Right Grant
- 2012-03-14 US US13/496,188 patent/US9732083B2/en active Active
- 2012-03-14 WO PCT/US2012/029104 patent/WO2012125746A1/en active Application Filing
- 2012-03-14 JP JP2013558143A patent/JP6140083B2/ja active Active
- 2012-03-14 CN CN201280020849.4A patent/CN103562208B/zh active Active
- 2012-03-14 CA CA2829939A patent/CA2829939C/en active Active
- 2012-03-14 AR ARP120100830A patent/AR085806A1/es active IP Right Grant
- 2012-03-14 KR KR1020137026970A patent/KR20140059164A/ko not_active Application Discontinuation
- 2012-03-14 MX MX2013010511A patent/MX345780B/es active IP Right Grant
- 2012-03-14 KR KR1020197025342A patent/KR102132574B1/ko active IP Right Grant
- 2012-03-14 AU AU2012229997A patent/AU2012229997B2/en active Active
- 2012-03-14 TW TW101108646A patent/TWI527818B/zh active
-
2013
- 2013-09-01 IL IL228220A patent/IL228220A/en active IP Right Grant
- 2013-10-11 ZA ZA2013/07583A patent/ZA201307583B/en unknown
-
2017
- 2017-07-07 US US15/643,760 patent/US10858360B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR085806A1 (es) | Inhibidores triciclicos de girasa | |
AR092538A1 (es) | Inhibidores de girasa triciclica | |
ES2618630T3 (es) | Composiciones terapéuticas y métodos de uso relacionados | |
ES2521596T3 (es) | Combinación del compuesto GlyT1 con antipsicóticos | |
SV2016005328A (es) | Nuevos derivados de pirazolo pirimidina y su uso como inhibidores de malt1 | |
CY1119220T1 (el) | Μονοκυκλικο παραγωγο πυριδινης | |
CO6251261A2 (es) | Derivados de 1- 82-amino-2-oxoalquil)-n(1h-indazol-5-il)pirrolidina-3-carboxamida | |
SA515361086B1 (ar) | Fasn مركبات وتركيبات جديدة لتثبيط | |
AR078609A1 (es) | 8-etil-6-(aril)pirido[2,3-d]pirimidin-7(8h)-onas, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de trastornos del sistema nervioso central,tales como depresion y canceres de ovario y renales, entre otros. | |
AR085549A1 (es) | DERIVADOS TRIAZOLIL PIPERAZINA Y TRIAZOLIL PIPERIDINA SUSTITUIDOS COMO MODULADORES DE g SECRETASA | |
PE20160501A1 (es) | Derivados de quinolizina sustituidos utiles como inhibidores de integrasa del vih | |
NI201400099A (es) | Composición para el control de plagas que incluye un derivado de iminopiridina novedoso | |
CY1121677T1 (el) | Ενωσεις διμεθυλοβενζοϊκου οξεος | |
AR088226A1 (es) | Derivados piperidinicos heterociclicos, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de enfermedades neurodegenerativas | |
UY32490A (es) | Inhibidores de beta-secretasa | |
AR068538A1 (es) | Compuesto heterociclico de 5 miembros con actividad supresora de la secrecion de acido | |
TR201911151T4 (tr) | Jak2 ve alk2 inhibitörleri ve bunların kullanım yöntemleri. | |
ES2653265T3 (es) | Morfinanos sustituidos y el uso de éstos | |
RU2012140961A (ru) | ПРОИЗВОДНОЕ 1,3,4,8-ТЕТРАГИДРО-2Н-ПИРИДО[1,2-a]ПИРАЗИНА И ЕГО ПРИМЕНЕНИЕ В КАЧЕСТВЕ ИНИБИТОРА ИНТЕГРАЗЫ ВИЧ | |
AR077695A1 (es) | Derivados de pirimidina como inhibidores del factor ixa | |
PE20142081A1 (es) | Inhibidores de quinurenina-3-monooxigenasa, composiciones farmaceuticas y metodo de uso de los mismos | |
AR088828A1 (es) | DERIVADOS DE CICLOHEXILAMINA QUE TIENEN ACTIVIDAD COMO AGONISTAS ADRENERGICOS b2 Y COMO ANTAGONISTAS MUSCARINICOS M3 | |
AR067613A1 (es) | Inhibidores de adn-pk, uso y sintesis de los mismos | |
AR080802A1 (es) | Compuestos de complejos de fe (iii) para el tratamiento y la profilaxis de los sintomas de deficiencia de hierro y anemias por deficiencia de hierro | |
AR085990A1 (es) | Derivados de 1-oxido de 3-hidroxiisotiazol utiles en el tratamiento de la diabetes y composiciones farmaceuticas que los contienen |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant, registration |